journal article·2026-02

An MSR1‐Targeting Glycolipid Platform for Imaging the Changes of Phagocytic Macrophages in the Progression of Atherosclerotic Plaque

Ming Zhai, Xiaomei Liu, Zhijun Lei, Qinyun Gu, Chendi Gao, Zi‐Han Chen, Ya Zeng, Xiangyun Xu, Wei Wang, Bingyu Li, Yong Fan, Yefei Shi, Guosong Chen, Wenhui Peng

Advanced Functional Materials· Volume 36· Issue 10
Publisher page

Abstract

Abstract The progression of atherosclerosis (AS) plaque is marked by a shift in the main cell component of phagocytic macrophages from myeloid‐derived to vascular smooth muscle cell (VSMCs)‐derived macrophages. It remains a great challenge to identify proper targeting markers and to image the changes of phagocytic macrophage, including myeloid‐derived or VSMCs‐derived macrophages. Herein, we propose macrophage scavenger receptor 1 (MSR1), as a detection marker of dynamic phagocytic macrophage changes in atherosclerotic plaques. To focus on this macrophage marker, we designed an MSR1‐targeting synthetic glycolipid platform called sulfated L‐fucopyranoside glycolipid (SFGL) SFGL is precisely fabricated based on a specially designed synthetic glycolipid with a well‐defined structure, and it can be further co‐assembled with functional components such as organic fluorescent molecules and inorganic gold nanoparticles to achieve multifunctionality. The study revealed the main cell component change of phagocytic macrophages from zsGreen positive (zsGreen + ) myeloid‐derived MSR1 (hi) macrophages to tdTomato positive (tdTomato + ) VSMCs‐derived MSR1 (hi) macrophages during AS progression in VSMCs lineage tracing atherosclerotic mice. This change indicates the progression of atherosclerotic plaque, as observed using Near‐Infrared (NIR) imaging and micro‐computed tomography (micro‐CT). Based on the results, SFGL, with its exceptional targeting ability and convenient functionalization, is a promising candidate for both basic macrophage‐tracking research and applications such as imaging and drug delivery.
Source: crossref · Quality: baseline

Research context

OpenAlex topics: Phagocytosis and Immune Regulation · Atherosclerosis and Cardiovascular Diseases · Immune cells in cancer

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Department of Cardiology Shanghai Tenth People's Hospital School of Medicine Tongji University Shanghai 200070 China

The State Key Laboratory of Molecular Engineering of Polymers and Department of Macromolecular Science Fudan University Shanghai 200441 China

School of Medicine Tongji University Shanghai 200092 China

Department of Chemistry Shanghai Key Laboratory of Molecular Catalysis and Innovative Materials and iChem Fudan University Shanghai 200441 China

Zucker School of Medicine at Hofstra/Northwell Lenox Hill Hospital New York 10075 USA

Funding

National Key Research and Development Program of China

References (37)

Show source-provided references
1. 10.1038/s41586-021-03392-810.1038/s41586-021-03392-8 ↗
2. 10.1111/pin.1320210.1111/pin.13202 ↗
3. 10.1186/1741-7015-11-11710.1186/1741-7015-11-117 ↗
4. 10.1016/j.jacc.2023.09.81410.1016/j.jacc.2023.09.814 ↗
5. 10.1161/CIRCULATIONAHA.114.01431010.1161/CIRCULATIONAHA.114.014310 ↗
6. 10.1016/j.jacc.2017.10.02410.1016/j.jacc.2017.10.024 ↗
7. 10.3171/2015.1.JNS14245210.3171/2015.1.JNS142452 ↗
8. 10.1016/j.jacc.2005.09.06810.1016/j.jacc.2005.09.068 ↗
9. 10.3390/ijms2409791010.3390/ijms24097910 ↗
10. 10.3389/fphar.2021.65296310.3389/fphar.2021.652963 ↗
11. 10.1093/cvr/cvac16110.1093/cvr/cvac161 ↗
12. 10.1007/978-3-319-54090-0_1110.1007/978-3-319-54090-0_11 ↗
13. 10.1002/advs.20230868610.1002/advs.202308686 ↗
14. 10.3390/ijms2301034010.3390/ijms23010340 ↗
15. 10.1016/j.phymed.2024.15534110.1016/j.phymed.2024.155341 ↗
16. 10.1056/NEJMoa170791410.1056/NEJMoa1707914 ↗
17. 10.1161/CIRCRESAHA.115.30636110.1161/CIRCRESAHA.115.306361 ↗
18. 10.1007/s10554-020-01957-810.1007/s10554-020-01957-8 ↗
19. 10.1111/j.1541-9215.2003.02108.x10.1111/j.1541-9215.2003.02108.x ↗
20. 10.1038/s41569-023-00880-410.1038/s41569-023-00880-4 ↗
21. 10.1007/s11307-021-01654-510.1007/s11307-021-01654-5 ↗
22. Qin J. · Int. J. Nanomed. · 2014 · 9 · 5575
23. 10.1038/s41467-022-35330-110.1038/s41467-022-35330-1 ↗
24. 10.1161/01.ATV.20.2.29010.1161/01.ATV.20.2.290 ↗
25. 10.1155/2011/85128010.1155/2011/851280 ↗
26. Shi M. · J. Am Heart. Assoc. · 2022 · 11
27. 10.3390/md1408014510.3390/md14080145 ↗
28. 10.3390/md1808037610.3390/md18080376 ↗
29. 10.1016/j.biomaterials.2011.01.02110.1016/j.biomaterials.2011.01.021 ↗
30. 10.1021/acsami.8b1792810.1021/acsami.8b17928 ↗
31. 10.1161/CIRCULATIONAHA.107.74118110.1161/CIRCULATIONAHA.107.741181 ↗
32. 10.1073/pnas.220144311910.1073/pnas.2201443119 ↗
33. 10.1002/adhm.20150012610.1002/adhm.201500126 ↗
34. 10.1016/j.biomaterials.2011.06.02610.1016/j.biomaterials.2011.06.026 ↗
35. 10.1021/acsnano.7b0204410.1021/acsnano.7b02044 ↗
36. 10.1039/C9NR03590G10.1039/C9NR03590G ↗
37. 10.1038/nbt.319210.1038/nbt.3192 ↗